

# FRESENIUS SE & CO. KGAA

ISIN: DE0005785604 WKN: 578560 Asset Class: Stock

## Company

2024/04/17 17:35:18

Price

**26.51**

EUR

Difference

**-0.38% (-0.10)**



## Contact Details

FRESENIUS SE & CO. KGAA Tel: +49-6172-608-0

-- Fax: +49-6172-608-2628

Else-Kröner-Strasse 1 Web: <http://www.fresenius.de>

61352 Bad Homburg E-mail: [pr-fre@fresenius.com](mailto:pr-fre@fresenius.com)

## Company Profile

Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment caters to individuals with renal diseases. The Fresenius Kabi segment specializes in lifesaving medicines and technologies. The Fresenius Helios offers expertise in inpatient and outpatient care as well as in telemedicine. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The company was founded by Eduard Fresenius on October 1, 1912 and is headquartered in Bad Homburg, Germany.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2023           |                        | 2022           |                        | 2021           |                        |
|---------------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
|                                       | Assets         | Liabilities and equity | Assets         | Liabilities and equity | Assets         | Liabilities and equity |
| <b>Current assets</b>                 | 12,520,000,000 |                        | 18,279,000,000 |                        | 17,461,000,000 |                        |
| <b>Common stock capital</b>           |                | 563,000,000            |                | 563,000,000            |                | 558,000,000            |
| <b>Fixed assets</b>                   | 32,764,000,000 |                        | 58,136,000,000 |                        | 54,501,000,000 |                        |
| <b>Equity capital of a company</b>    |                | 19,651,000,000         |                | 32,218,000,000         |                | 29,288,000,000         |
| <b>Cash and cash equivalents</b>      | 2,562,000,000  |                        | 2,749,000,000  |                        | 2,764,000,000  |                        |
| <b>Accrued liabilities</b>            |                | 1,189,000,000          |                | 1,790,000,000          |                | 2,184,000,000          |
| <b>Other assets</b>                   | -              |                        | -              |                        | -              |                        |
| <b>Current liabilities</b>            |                | 9,330,000,000          |                | 13,658,000,000         |                | 15,062,000,000         |
| <b>Prepayments and accrued income</b> | -              |                        | -              |                        | -              |                        |
| <b>Non-current liabilities</b>        |                | 16,303,000,000         |                | 30,539,000,000         |                | 27,612,000,000         |
| <b>Different income</b>               |                | -                      |                | -                      |                | -                      |
| <b>Other liabilities</b>              |                | 1,334,000,000          |                | 2,353,000,000          |                | 1,530,000,000          |
| <b>Total assets</b>                   | 45,284,000,000 | 45,284,000,000         | 76,415,000,000 | 76,415,000,000         | 71,962,000,000 | 71,962,000,000         |

## Balance notes

|                            | 2023    | 2022    | 2021    |
|----------------------------|---------|---------|---------|
| <b>Accounting standard</b> | IFRS    | IFRS    | IFRS    |
| <b>Employees</b>           | 193,865 | 316,920 | 316,078 |
| <b>Equity ratio</b>        | 44.83%  | 57.61%  | 55.00%  |
| <b>Debt-equity ratio</b>   | 123.04% | 73.59%  | 81.82%  |

## Others

|                         | 2023   | 2022   | 2021   |
|-------------------------|--------|--------|--------|
| <b>Tax Expense Rate</b> | 65.61% | 25.38% | 23.41% |

# FRESENIUS SE & CO. KGAA

ISIN: DE0005785604 WKN: 578560 Asset Class: Stock

## Income statement

|  | 2023           | 2022           | 2021           |
|--|----------------|----------------|----------------|
| <b>Turnover</b>  | 22,299,000,000 | 40,637,000,000 | 37,077,000,000 |
| <b>Net income</b>  | 353,000,000    | 1,372,000,000  | 1,818,000,000  |
| <b>EBIT</b>  | 1,139,000,000  | 3,250,000,000  | 4,072,000,000  |
| <b>Operating income before taxes</b>                                 | 727,000,000    | 2,746,000,000  | 3,559,000,000  |
| <b>Cash Flow</b>   | 4,562,000,000  | 4,198,000,000  | 5,078,000,000  |
| <b>Net interest income</b>   | -412,000,000   | -504,000,000   | -513,000,000   |
| <b>Research and development expenses</b>                             | 608,000,000    | 842,000,000    | 774,000,000    |
| <b>Income taxes</b>  | 477,000,000    | 697,000,000    | 833,000,000    |
| <b>Result from investments in subsidiaries, associates and other</b> | -12,000,000    | 68,000,000     | 93,000,000     |
| <b>Revenues per employee</b>   | 115,023        | 128,225        | 117,303        |

## Board of Directors

|                      |                               |
|----------------------|-------------------------------|
| Wolfgang Kirsch      | Chairman of Supervisory Board |
| Christoph Zindel     | Member of Supervisory Board   |
| Iris Löw-Friedrich   | Member of Supervisory Board   |
| Michael Albrecht     | Member of Supervisory Board   |
| Bernd Behlert        | Member of Supervisory Board   |
| Frauke Lehmann       | Member of Supervisory Board   |
| Grit Genster         | Member of Supervisory Board   |
| Holger Michel        | Member of Supervisory Board   |
| Konrad Kölbl         | Member of Supervisory Board   |
| Michael Diekmann     | Member of Supervisory Board   |
| Oscar Romero de Paco | Member of Supervisory Board   |
| Susanne Zeidler      | Member of Supervisory Board   |

## Members of Management Board

|                     |                               |
|---------------------|-------------------------------|
| Michael Sen         | Chairman of Managing Board    |
| Michael Moser       | Member of Executive Committee |
| Helen Ping Giza     | Member of Executive Committee |
| Pierluigi Antonelli | Member of Executive Committee |
| Robert Möller       | Member of Executive Committee |
| Sara Lisa Hennicken | Member of Executive Committee |